DHA
Depression
A double-blind, placebo-controlled
study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major
depression.
Marangell LB, Martinez JM, Zboyan
HA, Kertz B, Kim HF, Puryear LJ.
Mood Disorders Center, Department of Psychiatry, Baylor College
of Medicine, Suite 560, 6655 Travis Road, Houston, TX 77030, USA. laurenm@bcm.tmc.edu
OBJECTIVE: This study was an evaluation of the omega-3 fatty
acid docosahexaenoic acid (DHA) for the treatment of major depression. METHOD:
Thirty-six depressed patients were randomly assigned to receive DHA, 2 g/day,
or placebo for 6 weeks. Response was defined a priori as a > or =50% reduction
in the score on the Montgomery-Asberg Depression Rating Scale. Thirty-five participants
were evaluable; 18 received DHA, and 17 received placebo. RESULTS: Response
rates were 27.8% in the DHA group and 23.5% in the placebo group. The difference
in response rates between groups did not reach statistical significance. CONCLUSIONS:
This trial failed to show a significant effect of DHA monotherapy in subjects
with major depression.
Publication Types:
Click here to go to the PuraEPA website.
|
|
